TSTuulikki Sokka

Tuulikki Sokka

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tuulikki Sokka has a total of 173 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Glucocorticoid purchases and methotrexate persistence in early rheumatoid arthritis in Finland

    by P Pöllänen, H Salo, T Sokka-Isler, L Kuusalo, J Kärki, P Vähäsalo, M Backström, H Relas, V Rantalaiho, J Huhtakangas

  • Open Access

    COVID-19 incidence among Kenyan patients with and without inflammatory rheumatic disease

    by Benwillies Onchong’a, Tuulikki Sokka-Isler, Pekka Mäntyselkä, Ari Voutilainen

    Background: Inflammatory rheumatic diseases (IRDs) have been considered potential risk factors for COVID-19, but evidence from Africa remains limited. Aim: To investigate the association between IRDs and COVID-19 among general patients after hospital discharge in Nairobi, Kenya. Setting: The prospective cohort study was conducted at Mbagathi County Hospital, a major public hospital in Nairobi, Kenya. Methods: Patients were classified as IRD and non-IRD cases based on admission diagnosis. After discharge, 348 IRD and 2951 non-IRD patients were followed up for 2 years or until death. Cox proportional hazard models adjusted for baseline characteristics were executed to predict COVID-19 hazard in patients with versus without IRDs. Results: The cohort included 46.2% women. IRD patients were older (mean 64 years vs. 62 years; p < 0.001), more frequently alcohol drinkers (17.0% vs. 9.5%; p < 0.001), less often vaccinated against COVID-19 (74.0% vs. 78.0%; p = 0.031) and had higher body mass index (BMI) (mean 26.3 kg/m2 vs. 25.3 kg/m2; p < 0.001). The 2-year COVID-19 incidence rate per 100 person-years was 4.5 (95% confidence interval [CI]: 3–7) in IRD patients and 5.0 (95% CI: 4–6) in non-IRD patients. The age- and sex-adjusted hazard of COVID-19 among IRD versus non-IRD patients was 0.9 (95% CI: 0.6–1.4; p = 0.667). Conclusion: Inflammatory rheumatic diseases did not increase COVID-19 risk in this Kenyan cohort. Contribution: This study provides valuable African data on IRDs and COVID-19 risk, reflecting potential regional features in clinical practice and public health strategies.

  • Open Access

    Physician global assessment in rheumatoid arthritis—is there any logic?

    by Katriina Jäppinen, Paula Muilu, Reija Autio, Laura Kuusalo, Susanna Sihvonen, Tuulikki Sokka-Isler, Vappu Rantalaiho


  • Open Access

    Giant cell arteritis in Finland from 2010 to 2020: incidence, developing diagnostic methods and disease presentation

    by Lauri Kivitalo, Kirsi Taimen, Tuulikki Sokka-Isler, Anne Kerola, Joonas Rautavaara, Laura Pirilä, Markku Kauppi, Joel Malila, Laura Haara, Laura Ryyppö, et al.

    Objectives: To study the annual incidence, diagnostic methods used and clinical presentation of giant cell arteritis (GCA) over time in Finland. Methods: Newly diagnosed GCA patients from 2010 to 2020 were retrospectively identified from four healthcare districts in Finland. Medical records were reviewed and data on incidence, diagnostic methods, phenotype [cranial vs large vessel (LV)-GCA] and clinical presentation were analysed. Results: We identified 602 newly diagnosed GCA patients. The annual incidence was 9.0 cases/100 000 persons (95% CI 8.3, 9.7) ≥50 years of age and was significantly higher in the period 2016–2020 compared with the period 2010–2015 [11.3 (95% CI 10.1, 12.5) vs 7.0 (95% CI 6.2, 7.9), P < 0.001]. Imaging- or biopsy-confirmed diagnosis was recorded in 75% of GCA patients, while 25% had a clinical diagnosis. The proportion of imaging- or biopsy-confirmed diagnoses increased over time [64.7% (2010–2015) vs 82.2% (2016–2020)] while that of clinical diagnoses decreased. The use of imaging methods increased while the use of temporal artery biopsies decreased between the two time periods. LV-GCA was discovered more often in the period 2016–2020 when compared with 2010–2015 (34.0% vs 19.3% of patients). Conclusion: The incidence of GCA increased during the study period, as well as the proportion of imaging- or biopsy-confirmed diagnoses, probably due to more frequent use of advanced imaging methods. Additionally, patients with LV-GCA were more commonly identified.


  • Open Access

    Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial

    by Kristina Lend, Jon Lampa, Leonid Padyukov, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C Nordström, Michael T Nurmohamed, Anna Rudin, Mikkel Østergaard, Espen A Haavardsholm, et al.

    Objectives To investigate whether rheumatoid factor (RF), anti-citrullinated protein antibodies (ACPAs) and shared epitope (SE) allele-related genetic markers associate with treatment response to abatacept, certolizumab pegol or tocilizumab versus active conventional treatment (ACT). Methods Patients with treatment-naïve early rheumatoid arthritis were randomised in the NORD-STAR trial to ACT, certolizumab pegol, abatacept or tocilizumab, all with methotrexate. Centralised laboratory analyses for ACPA, RF and SE were performed. Clinical Disease Activity Index remission was analysed longitudinally with logistic generalised estimating equations. Differences in treatment effect across RF, ACPA and SE subgroups were assessed with interaction terms at 24 and 48 weeks, adjusted for sex, country, age, body mass index, Disease Activity Score of 28 joints based on C-reactive protein and smoking. Results In total, 778 patients were included. At 24 weeks, abatacept treatment showed a better response than ACT in the RF and/or ACPA-positive subgroups, but this effect was not significantly different from the negative subgroups. By 48 weeks, abatacept treatment showed better response regardless of RF/ACPA status. No differences were found across RF, ACPA, SE allele, valine at amino acid position 11 or valine-arginine-alanine haplotype subgroups for any biological treatment at 48 weeks. Conclusions Based on this randomised controlled trial, abatacept treatment was associated with a better response than ACT in the RF and/or ACPA-positive subgroup at 24 weeks, but this was no longer seen at 48 weeks; adding SE allele-related genetic markers did not strengthen the association. Moreover, ACPA, RF and SE allele-related genotypes were not, alone or in combination, associated with clinical responses of importance sufficiently strongly to warrant implementation in clinical practice. Trial registration number EudraCT 2011-004720-35; ClinicalTrials.gov NCT01491815.


  • Open Access

    Hyperinsulinemia counteracts inflammation by suppressing IFNγ and inducing senescence in CD4 + T cells of patients with rheumatoid arthritis

    by Malin C Erlandsson, Lauri Weman, Eric Malmhäll-Bah, Venkataragavan Chandrasekaran, Mahomud Tuameh, Karin Me Andersson, Sofia Töyrä Silfverswärd, Lisa M Nilsson, Tatiana Zverkova Sandström, Rille Pullerits, et al.

    Background: Clinical evidence connects hyperinsulinemia with obesity, and development of type 2 diabetes (T2D). However, its role in autoimmune conditions was questioned. We investigated consequences of hyperinsulinemia for development of T2D and CD4 T cell function in rheumatoid arthritis (RA). Methods: Incident T2D was prospectively studied in two independent RA cohorts and in gout patients matched to RA by age and gender, for 10 years. Effect of hyperinsulinemia and JAK-STAT signaling inhibition (JAKi) in CD4 T cells was studied by integrating transcriptional sequencing with direct effect of insulin, and JAKi on cell proliferation, DNA enrichment, and cytokine production. Results: T2D was 3.2-2.5 times less prevalent in RA compared to gout, particularly in females. Hyperinsulinemia predicted the development of T2D, regardless of metabolic parameters and insulin resistance. Additionally, hyperinsulinemia correlated with the senescence-associated high serum levels of IL6, IL8, and VEGF. Hyperinsulinemia, along with ex-vivo exposure of CD4 cells to insulin, inhibited cell cycle progression and induced DNA enrichment through the suppression of the PI3K-Src kinases and cell cycle promoting genes. It also reduced IFNγ production. JAKi-treated CD4 + cells regained insulin sensitivity, which activated glucose metabolism and facilitated senescence. This insulin-dependent mechanism promoted the accumulation of naïve CD4 cells in JAKi-treated patients. Conclusions: This study shows that insulin has important immunosuppressive ability controlling the adaptive immunity by suppressing IFNγ production and inducing senescence in the effector CD4 T cells. Inhibition of JAK-STAT signaling enhances insulin sensitivity and rejuvenates CD4 cell population in RA patients.


  • Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries

    by Bente Glintborg, Daniela Di Giuseppe, Johan Karlsson Wallman, Dan C Nordström, Bjorn Gudbjornsson, Merete Lund Hetland, Johan Askling, Gerdur Grondal, Tuulikki Sokka, Sella A Provan, et al.

    Background We aimed to describe the uptake of newer biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in psoriatic arthritis (PsA) in the Nordic countries and to compare their retention and effectiveness. Methods Patients with PsA starting a b/tsDMARD in 2012–2020 in five Nordic rheumatology registers were included. Uptake and patient characteristics were described, with comorbidities identified from linkages to national patient registries. One-year retention and 6-month effectiveness (proportions achieving low disease activity (LDA) on the Disease Activity Index for PSoriatic Arthritis based on 28-joint evaluation) for the newer b/tsDMARDs (abatacept/apremilast/ixekizumab/secukinumab/tofacitinib/ustekinumab) were compared with adalimumab through adjusted regression models stratified by treatment course (first, second/third, and fourth or more). Results In total, 5659 treatment courses with adalimumab (56% biologic-naïve) and 4767 courses with a newer b/tsDMARD (21% biologic-naïve) were included. The uptake of newer b/tsDMARDs increased from 2014 and plateaued in 2018. Patient characteristics appeared similar across treatments at treatment start. Adalimumab was more often used as the first course and newer b/tsDMARDs more often in biologic-experienced patients. Used as a second/third b/tsDMARD, the retention rate and the proportion achieving LDA were significantly better for adalimumab (rate 65%, proportion 59%) compared with abatacept (45%, 37%), apremilast (43%, 35%), ixekizumab (LDA only, 40%) and ustekinumab (LDA only, 40%), but not significantly different from other b/tsDMARDs. Conclusion Uptake of newer b/tsDMARDs occurred mainly in biologic-experienced patients. Regardless of mode of action, only a minority of patients starting a second or later b/tsDMARD course remained on drug and achieved LDA. Superior outcomes for adalimumab indicate that the positioning of newer b/tsDMARDs in the PsA treatment algorithm remains to be established.